SeaCrest Wealth Management’s Enzo Biochem, Inc. ENZ Stock Holding History

SeaCrest Wealth Management’s Portfolio ENZ Stock Details ENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-49	Closed	–	–	1910
2019 Q1	$0	Hold	49	–	–	﹤0.01%	2244
2018 Q4	$0	Hold	49	–	–	﹤0.01%	2320
2018 Q3	$0	Hold	49	–	–	﹤0.01%	2346
2018 Q2	$0	Hold	49	–	–	﹤0.01%	2302
2018 Q1	$0	Hold	49	–	–	﹤0.01%	2303
2017 Q4	$0	Buy	+49	New	+$468	﹤0.01%	2256

Other funds holding ENZ

HFA

Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EGA

Evermore Global Advisors Summit, New Jersey $26.3M AUM 7.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RAM

Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

SeaCrest Wealth Management's ENZ Position: Q2 2019 in Review

SeaCrest Wealth Management sold out of Enzo Biochem, Inc. (ENZ) in Q2 2019, closing a stake of 49 shares.

SeaCrest Wealth Management first reported a position in ENZ in Q4 2017 and held it in 6 quarters. The position peaked at $0 in Q1 2019. 95 funds tracked by Wall St. Rank hold ENZ as of Q2 2019.

SeaCrest Wealth Management reported no remaining Enzo Biochem, Inc. position as of Q2 2019 after selling out during the quarter.
SeaCrest Wealth Management sold 49 Enzo Biochem, Inc. shares in Q2 2019.
SeaCrest Wealth Management first reported a position in Enzo Biochem, Inc. in Q4 2017 and held it in 6 quarters.
SeaCrest Wealth Management's Enzo Biochem, Inc. position peaked at $0 in Q1 2019.
95 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q2 2019.

Based on SeaCrest Wealth Management's 13F filing for Q2 2019, filed 19 Jul 2019.